This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Increased Evolution of Regulations Affecting the Pharmaceutical Law Practice

November 2010
RegulationPharmaceutical

Abstract

The increase of regulations over the last two to five years for pharmaceutical companies has become a nightmare for sales representatives working for those companies and for internal staff charged with assuring the companies’ employees are following the most recent regulations affecting their actions every work day. One area where there has been an increase of regulations is state reports. Currently, pharmaceutical companies are reporting various payments or exchanges of financial value to physicians, healthcare providers (HCPs) and affiliated healthcare organization (HCOs) to meet the complex state specific filing requirements of 6 states and Washington DC. Since 2006, 20 states have introduced legislation requiring pharmaceuticals companies to make these disclosures and it is anticipated that more states will require the reporting. The current state reporting requirements are neither consistent from state to state and can be broadly interpreted regarding the definitions of reportable entities and/or the type of transactions to be reported. The current state reporting requirements include:

Author

Company

Fox Rothschild

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis. The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions. The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world. Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA. Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.

Related Papers

Self-Regulation of an Industry versus the Rule of Law
Self-regulation is an honourable concept. Proponents of the system emphasise the relative amiability and expediency of dispute resolution mechanisms, and remind industry that to the extent that it is not...Read more
Portrait image of Howard Snoyman
Howard Snoyman
Head: Legal and Ethics, Discovery Health Medical Scheme, South Africa
Left to Their Own Devices
The European Union (“EU”) has among its most fundamental goals and principles a convergence of the economies of, and a weakening of internal frontiers between, its member states. Economic...Read more
Portrait image of Patrik Plöen
Patrik Plöen
Head of Legal, Internationa, Markets, Nestlé Skin Health, Sweden
The Globalization of Clinical Trials - Challenges, Opportunities and a Path Forward
In recent years, pharmaceutical companies have expanded clinical research in emerging markets around the world and increasingly involving populations that traditionally have had limited or no access to clinical trials...Read more
Portrait image of Marc Wilenzick
Marc Wilenzick
Chief Compliance Counsel, R&D, Pfizer Inc, USA
Portrait image of Justin McCarthy
Justin McCarthy
SVP Global Policy and International Public Affairs, Pfizer Inc., USA
Portrait image of Cara Cuenot
Cara Cuenot
Lead counsel for the BioCorrection Research Unit, Pfizer Inc, USA
United States Jurisdiction Abroad
The United States applies their jurisdiction abroad under several instances. This is something very important for U.S. based corporations with global operations to understand, since there might be in a...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA